pevonedistat and Leukemia

The NEDD8-activating enzyme (NAE) initiates neddylation, the cascade of post-translational NEDD8 conjugation onto target proteins. MLN4924, a selective NAE inhibitor, has displayed preclinical anti-tumor activity in vitro and in vivo, and promising clinical activity has been reported in patients with refractory hematologic malignancies. Here, we sought to understand the mechanisms of resistance to MLN4924. K562 and U937 leukemia cells were exposed over a 6 month period to MLN4924 and populations of resistant cells (R-K562(MLN), R-U937(MLN)) were selected. R-K562(MLN) and R-U937(MLN) cells contain I310N and Y352H mutations in the NAE catalytic subunit UBA3, respectively. Biochemical analyses indicate that these mutations increase the enzyme's affinity for ATP while decreasing its affinity for NEDD8. These mutations effectively contribute to decreased MLN4924 potency in vitro while providing for sufficient NAE function for leukemia cell survival. Finally, R-K562(MLN) cells showed cross-resistance to other NAE-selective inhibitors, but remained sensitive to a pan-E1 (activating enzyme) inhibitor. Thus, our work provides insight into mechanisms of MLN4924 resistance to facilitate the development of more effective second-generation NAE inhibitors.

Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cullin Proteins; Cyclopentanes; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genotype; Humans; K562 Cells; Leukemia; Models, Molecular; NEDD8 Protein; Point Mutation; Protein Binding; Protein Conformation; Pyrimidines; Structure-Activity Relationship; U937 Cells; Ubiquitin-Activating Enzymes; Ubiquitins